Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.50    -0.50 (-0.10%)
Bid:
502.00
Ask:
503.00
Spread: 1.00 (0.199%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

9 Feb 2017 07:00

9 February 2017 – Tate & Lyle PLC

TRADING STATEMENT

Tate & Lyle issues the following trading statement for the three months ended 31 December 2016.

The Group continued to perform strongly in the third quarter with profit in constant currency ahead of the comparative period in both divisions. Speciality Food Ingredients performed in line with expectations while in Bulk Ingredients profit was ahead of our expectations.

In Speciality Food Ingredients, excluding Food Systems and SPLENDA® Sucralose, profit was ahead of the comparative period benefiting from good commercial execution and strong manufacturing performance. Underlying volume was broadly in line with the comparative period. As in the first half, demand in North America continued to be soft with volume lower, whilst in Europe, Middle East and Africa underlying volume growth was robust. Strong volume growth in Latin America largely offset weaker demand in Asia Pacific. Food Systems profit continued to be held back by lower volume and SPLENDA® Sucralose profit was ahead of the comparative period benefiting from the consolidation of production to a single facility.

In Bulk Ingredients, North American sweetener volume remained robust. The calendar 2017 bulk sweetener pricing round is now substantially complete and is expected to deliver modest margin gains in the fourth quarter. Commodities performance was satisfactory and somewhat ahead of our expectations.

Encouraged by performance in the quarter, we now expect the Group’s performance in constant currency for the full year to be modestly ahead of our expectations at the time of our Half Year Results in November 2016.

END

A conference call will be held today at 08.00am GMT, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 23 February 2017.

UK replay number: +44 (0) 20 8196 1998

Replay access PIN: 7131354

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 25 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2016, Tate & Lyle sales totalled £2.4 billion. For more information, please visit http://www.tateandlyle.com.

SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170208006005/en/

Copyright Business Wire 2017

Date   Source Headline
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.